Drug intelligence / Profile preview

ALDP001

Development stage: Unknown
Lead developer: Alixer Nexgen Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

ALDP001 is an intranasal spray formulation of alcaftadine (0.125%), a small molecule H1 histamine receptor antagonist. It is being developed by Alixer Nexgen Therapeutics, a subsidiary of Alkem Laboratories, for the treatment of seasonal allergic rhinitis. The drug is designed to alleviate allergic symptoms by blocking the effects of histamine and potentially through mast cell stabilization. It is currently being evaluated in Phase 2 adaptive clinical trials using an allergen challenge chamber (ECC) to determine the optimal dose and dosing frequency for adults with seasonal allergic rhinitis under controlled allergen exposure.

Other names: alcaftadine nasal spray

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ALDP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALDP001.

Explore the full profile